BASi Recieves a European Patent

January 6, 2009

Company News Release

BASi has announced the awarding of the new European patent for their Culex Automated In Vivo Sampling System.

BASi Recieves a European Patent for Culex

(January 6, 2008; WARWICKSHIRE, UK)-BASi is proud to announce the awarding of the new European patent for their Culex® Automated In Vivo Sampling System. The patent is valid until 2019 and is effective in Germany, Denmark, France, UK and Sweden.

The Culex Automated In Vivo Sampling System is designed to collect pharmacokinetic and pharmacodynamic (PK/PD) data during the course of drug metabolism experiments. The Culex systems can collect blood, bile, urine, feces, dialysates and more – with greatly reduced trauma and stress from awake, freely moving animals.  In addition, an electronic report on both the dosing and the blood sampling experiments is generated automatically.  

Culex’s versatility makes possible a wide variety of PK/PD studies in small rodents, greatly reducing the number of animals used whilst increasing the number of samples per animal, and allowing dosing and sampling of animals, day or night.  

With Culex, researchers gain the unique opportunity to undertake full PK/PD studies in the same animal.  In addition, researchers can monitor a wide range of physiological parameters such as blood pressure, body temperature, respiratory rates, ECG, urinary frequency and animal movement alongside more traditional pharmacokinetic parameters.

           BASi has recently introduced the Culex®-L, Automated Large Animal In Vivo Sampling System. This instrument utilizes the same concept as the popular rodent-orientated Culex system but for pigs and other larger mammals.


About BASi
BASi provides contract research services and specialized instrumentation and accessories for electrochemistry and in vivo sampling products to the world’s leading drug development companies. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new drugs to market. Visit www.BASInc.com for more information about BASi.

Related Content:

News